Clinical Trials

  • A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    Principal Investigator:

    Nobuko Hijiya, MD
    This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60 years with newly diagnosed early-stage cHL and will investigate the targeted CD30-antibody drug conjugate, Brentuximab Vedotin (Bv), with PD-1 blockade (nivolumab) compared with a standard chemotherapy regimen, with or without radiotherapy.

  • A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML

    Principal Investigator:

    Nobuko Hijiya, MD
    This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA), that can improve a disease or condition. Participants will receive Imeletstat intravenously (IV), and undergo study procedures such as blood and cerebrospinal fluid sample collection, as well imaging scans.

  • Assessment of Pruritis (Itch) in Children with Primary Sclerosing Cholangitis

    Principal Investigator:

    Mercedes Martinez, MD
    The purpose of this study is to better understand how common and how severe pruritis (itching) is in children and adults under 21 years of age with Primary Sclerosing Cholangitis (PSC). The study involves the completion of two short online surveys. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).

  • Assessment of Pruritis (Itch) in Children with Primary Sclerosing Cholangitis

    Principal Investigator:

    Mercedes Martinez, MD
    The purpose of this study is to better understand how common and how severe pruritis (itching) is in children and adults under 21 years of age with Primary Sclerosing Cholangitis (PSC). The study involves the completion of two short online surveys. If you have any questions regarding this study, please contact the Transplant Clinical Research Center ( TCRC).

  • CAUSE: Childhood Asthma in Urban Settings

    Principal Investigator:

    Meyer Kattan, MD
    If you or your child has asthma and/or taking asthma medication daily call 347-344-3000 for more information about joining an asthma registry and opportunities to participate in other asthma research studies.

  • CAUSE: Childhood Asthma in Urban Settings

    Principal Investigator:

    Meyer Kattan, MD
    If you or your child has asthma and/or taking asthma medication daily call 347-344-3000 for more information about joining an asthma registry and opportunities to participate in other asthma research studies.

  • Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment & in Circulation (iSYNAPSE)

    Principal Investigator:

    Mercedes Martinez, MD
    The iSYNAPSE study is a multi-center clinical trial for children who have received a liver transplant and are taking a medication that suppresses the immune system. The goal of the study is to see if we can safely reduce the dose of the immunosuppressive medication that participants are taking. Study participation will last 18 months and will consist of in-person visits, phone calls, and lab visits. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).

  • Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment & in Circulation (iSYNAPSE)

    Principal Investigator:

    Mercedes Martinez, MD
    The iSYNAPSE study is a multi-center clinical trial for children who have received a liver transplant and are taking a medication that suppresses the immune system. The goal of the study is to see if we can safely reduce the dose of the immunosuppressive medication that participants are taking. Study participation will last 18 months and will consist of in-person visits, phone calls, and lab visits. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).

  • Genetics of Early Childhood Obesity (GECO) Study at Columbia

    Principal Investigator:

    Vidhu Thaker, MD
    We will enroll children with severe early onset obesity (BMI greater than 99th percentile) diagnosed prior to 6 years of age or other endocrine disorders. We will ask questions about their health, eating behavior and perform a brief physical examination. We will collect saliva or blood to perform genetic testing. We will also invite family members to participate in the genetic study.

  • Maralixibat for Treatment of Cholestatic Pruritus (MRX-802 EXPAND)

    Principal Investigator:

    Mercedes Martinez, MD
    The purpose of this study is to determine whether the investigational drug (maralixibat) is safe and effective in children and participants who have cholestatic liver disease with pruritus (itch) that has been responding to other therapies, and who have no other treatment options. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).

Pages

Back to top